Singapore markets closed
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,461.12 -8.18 (-0.15%) Dow
38,985.34 -126.82 (-0.32%) Nasdaq
17,752.83 +35.18 (+0.20%) Bitcoin USD
61,614.54 -341.39 (-0.55%) CMC Crypto 200
1,280.16 -3.62 (-0.28%)
ITCI Nov 2024 80.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:49PM EDT. Market open.
| Previous close | 9.75 |
| Open | 8.80 |
| Bid | 10.50 |
| Ask | 11.80 |
| Strike | 80.00 |
| Expiry date | 2024-11-15 |
| Day's range | 8.80 - 9.75 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.